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Abstract
Background
Tumor treating fields (TTFields) are increasingly used in the treatment of glioblastoma.
TTFields inhibit cancer growth through induction of alternating electrical fields. To opti-
mize TTFields efficacy, it is necessary to understand the factors determining the strength
and distribution of TTFields. In this study, we provide simple guiding principles for clini-
cians to assess the distribution and the local efficacy of TTFields in various clinical
scenarios.
Methods
We calculated the TTFields distribution using finite element methods applied to a realistic
head model. Dielectric property estimates were taken from the literature. Twentyfour tumors
were virtually introduced at locations systematically varied relative to the applied field. In
addition, we investigated the impact of central tumor necrosis on the induced field.
Results
Local field “hot spots” occurred at the sulcal fundi and in deep tumors embedded in white
matter. The field strength was not higher for tumors close to the active electrode. Left/right
field directions were generally superior to anterior/posterior directions. Central necrosis
focally enhanced the field near tumor boundaries perpendicular to the applied field and intro-
duced significant field non-uniformity within the tumor.
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Conclusions
The TTFields distribution is largely determined by local conductivity differences. The well
conducting tumor tissue creates a preferred pathway for current flow, which increases the
field intensity in the tumor boundaries and surrounding regions perpendicular to the applied
field. The cerebrospinal fluid plays a significant role in shaping the current pathways and fun-
nels currents through the ventricles and sulci towards deeper regions, which thereby experi-
ence higher fields. Clinicians may apply these principles to better understand how TTFields
will affect individual patients and possibly predict where local recurrence may occur. Accu-
rate predictions should, however, be based on patient specific models. Future work is
needed to assess the robustness of the presented results towards variations in conductivity.
Introduction
Glioblastoma multiforme (GBM) is a severe form of brain cancer with a particularly poor
prognosis. Current treatment consists of surgical resection of tumor tissue followed by radia-
tion and chemotherapy [1–7]. In recent years, an increasing number of neuro-oncology units
around the world have included a supplementary treatment modality called tumor treating
fields (TTFields) for both recurrent and newly diagnosed GBM [8–10]. TTFields utilize alter-
nating currents generated by electrode arrays placed on the scalp of the patient to induce low
intensity electrical fields in the brain and tumor tissue. The technology is composed of two
portable and battery-powered current sources, each connected to a separate pair of 3x3 elec-
trodes arrays (see below). The current sources are activated sequentially as square on-off pulses
of 1s duration and deliver a maximum peak-to-peak current of 1.8A. The level of current is
adjusted to maintain a skin temperature below a critical level of 41˚C. Skin temperature is
measured by sensors located in the center of the electrodes’ discs. Clinical efficacy depends on
the level of compliance and device “on-time”, and it is recommended that the device should
be active for at least 18 hours per day for patients to benefit from the treatment [11] (https://
www.optune.com/content/pdfs/Optune_PIOM_8.5x11.pdf).
Early studies established that TTFields are able to significantly impair tumor growth in
vitro [12,13]. The same studies also clarified that the inhibiting impact of TTFields on tumor
growth depends on the strength of the induced field. Specifically, the lower threshold of
growth rate inhibition was identified to be 100 V/m, and a field intensity of 225 V/m was
shown to cause regression of the tumor culture. Recent studies have shed important light on
the mechanism of action and shown that TTFields disrupt microtubule assembly and thereby
chromosome segregation during mitosis [14]. Furthermore, TTFields prevent proper assembly
of septin molecules at the cleavage furrow during cytokinesis, resulting in ectopic membrane
blebbing and abnormal mitosis [15]. In addition, the hourglass shape of the mitotic cell in telo-
phase causes considerable inhomogeneity of the intracellular field distribution. This induces
dielectrophoretic forces [16] which act on polarizable particles in the cell, such as organelles
and macromolecules, forcing them to move in the cytosol and aggregate close to the furrow
region, thereby interfering with proper cell division [12,13]. The fact that TTFields primarily
interferes with dividing cells causes the technology to preferentially interact with tissues with a
high rate of cell mitosis, such as cancerous tissues.
Clinical trials have demonstrated promising results with TTFields therapy for both re-
current and newly diagnosed GBM [17–23]. In particular, TTFields for recurrent GBM per-
form equally well as “best physicians’ choice chemotherapy” but is associated with far less
Impact of tumor position and conductivity on TTFields distribution
PLOS ONE | https://doi.org/10.1371/journal.pone.0179214 June 12, 2017 2 / 21
Grant "Basics" sponsored by NovoNordisk fonden
(recipients: Hartwig Siebner, Axel Thielscher & Lars
K. Hansen, Grant Nr. 11413). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: Anders Rosendal Korshoej
has received funding from Novocure Ltd. to
support the clinical trial ’Enhancing Optune Therapy
with Targeted Craniotomy’ (clinicaltrials.gov
identifier NCT02893137). The remaining authors
have no competing interests. This does not alter
our adherence to PLOS ONE policies on sharing
data and materials.
discomfort and adverse events [17]. For newly diagnosed GBM, TTFields increased the
median overall survival by approximately five months when applied in addition to the stan-
dard radio-chemotherapy regimen [18,21,23–25].
In order to optimize the clinical implementation of TTFields and fully exploit the utility of
the technology, it is very important to gain information about the distribution of the induced
electrical field in the brain [12,26–31]. Recent work has shed light on several aspects of this
area, e.g. the characterization of various models to calculate the field distribution [26,28–31],
and the influence of tumor morphology and electrode positioning on the induced field and
expected treatment efficacy [27]. Despite the increasing focus on understanding the biophysics
of TTFields, several questions remain unanswered. In this study, we aim to address some of
these issues and develop intuitive rules of thumb to help clinical end users to better understand
the nature of the TTFields therapy in various clinical scenarios. Particularly, we have investi-
gated the relationship between the electrical field strength in the region of pathology and 1)
the distance between the tumor center and the active electrodes, 2) the type of tissue surround-
ing the tumor, 3) the topographical relation of a tumor to high conductivity CSF pathways
such as superficial sulci, and 4) the presence of central necrosis in the tumor. Investigations
were conducted using computer simulation of TTFields therapy in a human head model with
a virtual cancer lesion.
Methods
The electric field distribution was calculated in a realistic head model using a finite element
approximation of Laplace’s equation for the electrostatic potential [26,28–30,32,33]. This
approximation is valid because the electromagnetic wavelengths in the modeled biological tis-
sues are much larger than the size of the head [28]. Therefore, the solution can be computed
by solving the complex quasi-static Laplace equation,r  ~srV ¼ 0 for the electric potential
with the complex conductivity ~s ¼ sþ ioε, where ε is the permittivity, σ the electrical con-
ductivity, i the imaginary unit, and ω = 2πf the angular frequency. Furthermore, recent studies
by Wenger et al, 2015 [29], have established that the impact of permittivity is negligible at
intermediate frequencies of TTFields, and therefore this parameter may be neglected and the
model simplified to an electrostatic formulation when calculating the electric potential. Calcu-
lations were performed using the SimNIBS software (www.simnibs.org) [34]. As previously
described [35,36], Dirichlet boundary conditions were applied and the electrodes were set to
fixed (arbitrarily chosen) potentials. The residuals for the conjugate gradient solver were
required to be<1E−9. The electric field was computed by taking the numerical gradient of the
electric potential, and the current density was determined from the electric field using Ohm’s
law. Finally, the potential difference of the electric field values and the current densities were
linearly rescaled such that the desired current strength was passing through the electrodes.
A peak current strength of 900 mA was simulated as input to each 3x3 electrode array in a
pair, corresponding to a peak-to-peak amplitude of 1.8A for the alternating currents. The elec-
trode array configuration was equivalent to the Optune™ technology used for clinical TTFields
therapy, i.e. two pairs of ceramic electrode arrays were assumed to be activated sequentially,
each array consisting of nine electrodes of 20 mm diameter arranged in a 3x3 array structure.
The center-to-center distances between neighboring electrodes were 45 mm and 22 mm,
respectively (Fig 1A). It was assumed that the current was provided by two separate and
sequentially active sources. In the simulations, the left and posterior arrays acted as the respec-
tive sources, while the right and anterior arrays were the corresponding sinks. Calculations
were performed using a realistic head model based on MRI data from a healthy subject (avail-
able at simnibs.org).
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In order to directly quantify the influence of tumor location relative to the electrode arrays,
all arrays were placed to define a transversal plane which was used to build up a reference coor-
dinate system, as follows: The head model was initially linearly transformed to the Talairach
coordinate system [37]. The left/right (L/R) electrode array pair was placed initially with cen-
ters located above the respective ear canals at equal distances (Fig 1A). The line between the
centers of the left and right arrays was defined as the x-axis with positive values to the right
and negative values to the left. The frontal electrode was then placed on the forehead in the
plane normal to the x-axis at x = 0 mm and such that the lower boundary of the array was
close to the supraorbital margin equivalent to a typical placement in clinical TTFields therapy.
The line between the origin and the frontal electrode center was defined as the y-axis with pos-
itive values in the anterior direction. The center of the posterior electrode was then placed at
the intersection of the y-axis and the scalp in the occipital region. The z-axis was defined as
normal to the xy-plane at the origin, thereby completing an orthogonal right-handed coordi-
nate system (Fig 1B). Electrodes were paired left with right (L/R) and anterior with posterior
Fig 1. Visualization of electrode placement, coordinate system and tumor locations. (A) Placement of electrodes on the scalp. (B) Visualization of the
coordinate system used to reference tumor location. (C-E) Depiction of all tumor locations relative to the coordinate system (x, y, z) shown in front, left and
top views. X-translations (mm): (30, 0, 0), (32.5, 0, 0), (35, 0, 0), (37.5, 0, 0), (42.5, 0, 0), (45, 0, 0), (47.5, 0, 0), (50, 0, 0). Y-translations (mm): (40, -40, 0),
(40, -30, 0), (40, -25, 0), (40, -20, 0), (40, -10, 0), (40, 5, 0), (40, 10, 0), (40, 15, 0), (40, 20, 0), (40, 25, 0), (40, 30, 0). Z-translations (mm): (40, 0, -30), (40, 0,
-25), (40, 0, -10), (40, 0, 10), (40, 0, 20).
https://doi.org/10.1371/journal.pone.0179214.g001
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(A/P) to mimic a realistic treatment scenario. Tumors were placed with varying x, y and z
coordinates in order to represent a wide and clinically relevant range of tumor positions within
the cerebral hemisphere. Translations were performed along the defined axes around a central
hemispheric position at x = 40 mm, y = 0 mm, and z = 0 mm (Fig 1C). The most medial tumor
position was chosen to respect the boundary of the lateral ventricle, and the boundaries of the
tumor and ventricle were separated by approximately 4 mm. Similarly, translations in the lat-
eral, cranial, caudal, anterior and posterior directions were chosen to keep the entire tumor
volume within the dural boundary (i.e. CSF surface), albeit such that the range of positions
represented was as wide as possible and encompassing both cortical and subcortical positions.
Extreme values of the translations thus defined the closest possible placement of the tumor to
the ventricular or dural boundary in the given direction. The ranges of tumor positions are
shown in Fig 1C–1E, and the exact coordinates are stated in the corresponding figure caption.
The original head mesh was segmented into five tissue types, namely skin, bone, cerebrospi-
nal fluid (CSF), gray matter (GM) and white matter (WM). Spherical tumor lesions were sub-
sequently introduced by post-processing of the mesh. All lesions had external diameters of 20
mm and inner core diameters of 14 mm, corresponding tumor sizes as previously investigated
by Miranda et al. [27–29]. For each location of the tumor, two scenarios were investigated: 1)
Tumor with central necrosis, i.e. isotropic conductivity of 1.00 S/m in the inner core, and a 3
mm peripheral brim of active tumor tissue with isotropic conductivity 0.24 S/m, 2) “Solid”
tumor with no necrosis, but homogeneous tumor tissue (isotropic conductivity 0.24 S/m)
throughout the entire volume. Isotropic conductivity estimates corresponded to previous
in vivo measurements at comparable frequencies [38–40]. For GM and WM, anisotropic con-
ductivity tensor estimates were obtained using diffusion MRI and a direct mapping scheme
[41,42]. The conductivity values for the remaining tissue types were as follows: Skin 0.465 S/m;
bone 0.010 S/m; and CSF 1.654 S/m. These values are based on average values obtained from
in vitro and in vivo experiments at comparable frequencies [43–45]. Comparable values have
been reported in a recent review [40] of electrical properties of biological tissues at frequencies
below 1 MHz, and recent TTFields modeling studies have also employed values in this range
[28,29]. Although the conductivity values used in this study are within the range of commonly
used and accepted values, it should be emphasized that the dielectric properties of biological
tissues have not been firmly established. Therefore some variation in the results should be
expected based on the choice of conductivity estimate. A recent study by Wenger et al, 2015
[29], has investigated and characterized the sensitivity of FEM models of TTFields with regards
to variations in dielectric properties. We kindly refer the reader to this article for a more elabo-
rate discussion of this matter.
TTFields “dosage” was quantified throughout the entire head model as the strength (Euclid-
ean norm) of the induced field vectors. The average field strength experienced by a tumor at
any given position was quantified as the median field strength within the volume and the
homogeneity of the field distribution was evaluated by the interquartile range (IQR) of the
field estimates. Low values of field strength IQR represented a uniformly distributed field in
the tissue, while high IQR values represented large local variability of field strength within the
tissue of interest.
Results
Importance of tumor location relative to the electrode arrays
Fig 2 shows the median field strengths induced in tumors placed at various distances along
each axis of the defined coordinate system (see Methods). Lateral displacement of the tumor
(x-axis) resulted in gradual but considerable reduction of the field strength induced by the L/R
Impact of tumor position and conductivity on TTFields distribution
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electrode array pair for both necrotic and solid tumors (~45 V/m for 20 mm lateral displace-
ment; Fig 2A). Conversely, lateral translation caused a gradual increase in the field strength
induced by the A/P electrode pair, although this effect was less pronounced (15 V/m for 20
mm lateral displacement). Displacement in the anterior/posterior direction (y-axis) resulted in
more variable field strength estimates, although there was a slight tendency toward lower field
strengths with anterior tumor locations. Results were comparable for both the L/R and A/P
electrode array pairs. Displacement in the caudo-cranial direction (z-axis) resulted in a slight
reduction of field strength induced by the L/R electrode pair but a slight increase induced by
the A/P pair. The topographical field distributions at all different tumor locations are pre-
sented as videos in the supplementary information S1–S6 Files. The videos illustrate changes
in the topographical field distribution, as the tumor is displaced along the x-, y-, and z-axes,
respectively.
Fig 2. Median and IQR of the field strength in the tumor tissue. Ordinate, V/m, relative to the distance of the tumor center from the origin
(abscissa, mm; black circles L/R array pair, red circles A/P array pair). (A) Median field strength in tumor tissue. (B) IQR of the field strength in
tumor tissue. Results are shown for solid tumors (lower row) and tumors with central necrosis (upper row).
https://doi.org/10.1371/journal.pone.0179214.g002
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As shown in Fig 2 and S1–S6 Files, the relationship between the tumor position and the
electrical field strength was complex. The relationship was likely determined by the electrical
properties of the tumor relative to the surrounding tissue, rather than merely the absolute
distance to the active electrodes. As evident from Fig 3 and S1 File, the field strength during
activation of the L/R pair was highest for medial tumor positions, i.e. when the tumor was
embedded in the low conductivity white matter. In this case, the induced field was perpendicu-
lar to the direction of the white matter fiber bundles, which had low anisotropic conductivity
in the left/right direction. This created a significant “conductivity barrier” in the L/R direction,
so that the current flow through the better-conducting tumor region was increased, thereby
increasing the field intensity at the lateral and particularly the medial tumor borders. In order
to examine the significance of tissue anisotropy in shaping these effects, we performed simula-
tions where GM and WM were assigned isotropic conductivity values calculated as the arith-
metic mean (mean conductivity, MC) of the anisotropic conductivities (eigenvalues). These
simulations are presented in Fig 4, which shows the difference in absolute field strengths when
the distribution was calculated using an anisotropic conductivity model (directional mapping),
as previously described, and the isotropic conductivity model. As evident from Fig 4, the
field calculated by using directional conductivity mapping and L/R electrode activation was
higher compared to the MC approach in the deep white matter bundles, such as the internal
capsule, corona radiata and superior longitudinal fascicle. This was the result of the fact that
the conductivity in L/R direction was lower than the mean value, due to the anisotropy of the
WM bundles. At the same time, a significant amount of current was injected into the region
through the sulcal CSF pathways (see below—Fig 5, Panel A), which further increased the field
strengths in the tumor region. Qualitatively, similar observations were true for A/P electrode
activation, however given the ninety-degree rotation of the induced field relative to the L/R
field, the directional mapping approach resulted in higher gyral field strengths compared to
the MC approach (Fig 4). This was due to the fact that gyral fiber bundles are largely oriented
perpendicularly to the A/P direction, causing a low “anisotropic” A/P conductivity. Although
conductivity values were generally higher in the A/P direction in deep white matter tissue
compared to the mean values, we did not observe significant differences between the fields
induced by the A/P pair in these regions (Fig 4). This observation may reflect the fact that con-
siderable amounts of current were shielded from some parts of the deep WM, due to neighbor-
ing frontal and occipital WM bundles perpendicular to the A/P direction, so that the current
was shunted around the region through CSF pathways including the ventricles (Figs 5 and 6).
Lateral positioning of the tumor (e.g. x = 50 mm) increased the A/P induced field in the
anterior and posterior parts of the tumor, while the L/R induced field was reduced (S1 and S2
Files). In the lateral position, the tumor was surrounded by gyral WM fiber bundles in L/R ori-
entation, which had low anisotropic conductivity in the A/P direction. Given the low conduc-
tivity of those fiber bundles in the direction of the current flow, the current flow through the
better conducting tumor tissue was increased, and this in turn increased the induced field in
the anterior and posterior borders of the tumor. By the same arguments as above, the opposite
was observed for the L/R pair.
The concept that field strengths in the tumor are strongly determined by the spatial conduc-
tivity distribution in its neighborhood is further supported by the observation that the L/R
electrode pair tended to induce higher field strengths in parts of tumors bordering a sulcus, i.e.
CSF boundary, directly (Fig 7A and 7C–7E and S3 File). This follows from the general fact that
current is transmitted along the path of least resistance and therefore has a tendency to travel
along the CSF-filled sulci parallel to the L/R field (Figs 5 and 7B). This induced high current
densities in the sulci and thereby high field strengths in the sulcal fundi in the direction of
current flow. These points therefore tended to define local “hot spots” in the electrical field
Impact of tumor position and conductivity on TTFields distribution
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Fig 3. Axial visualization of TTFields distribution in laterally displaced tumor. Field distribution induced by the L/R (left column) and A/P (right
column) array pairs, respectively, upon lateral displacement (x-axis) of the tumor. The axial section corresponds to the xy-plane at z = 0. Each row
Impact of tumor position and conductivity on TTFields distribution
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distribution induced by L/R oriented electrode pairs, and tumors located close to these points
experienced higher treatments efficacy.
In order to further illustrate the impact of the spatial conductivity distribution in the neigh-
borhood of the tumor, we investigated the field distribution induced in a head model in which
the tumor had been placed strategically to illustrate the concept. First let us review Fig 5, which
shows the distributions of current density (Panel A) and electric field (Panel B) together with a
directionally encoded color map of the tissue anisotropic conductivity (Panel C). This figure
shows the increased current flow through the well-conductive superficial CSF pathways. In
addition, it shows that these currents tend to induce high field strengths in regions where they
enter the low-conductive WM. Thus, we would expect the A/P field direction to induce high
field intensity in a tumor located near the genu of the corpus callosum. This is due to the fact
that significant amounts of current are directed towards this region through the superior sagit-
tal fissure (shunting the currents towards the tumor), and because the WM surrounding the
represents a specific tumor location with gradual lateral displacement from top to bottom (30 mm to 50 mm). The tumor shell is outlined with a dotted,
black circle. The field strength in the tumor is largely influenced by the conductivity of the surrounding tissue in the direction of the applied field.
https://doi.org/10.1371/journal.pone.0179214.g003
Fig 4. Comparison of field distribution in brain with anisotropic vs. isotropic conductivity. Fig 4 shows the absolute
difference in field strength, ΔE, between the simulations performed, assuming either anisotropic or isotropic conductivity in WM
and GM. Results are shown for each electrode pair separately (the L/R pair shown in the left column, the A/P pair in the right
column) in color coding, with positive values signifying a higher field strength in the anisotropic model, and negative values
signifying a higher field strength in the isotropic model.
https://doi.org/10.1371/journal.pone.0179214.g004
Impact of tumor position and conductivity on TTFields distribution
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Fig 5. Current density and field distribution in context of anisotropic tissue conductivity. (A) Axial
section showing current density (0–200 A/m2 color-coding), (B) field distribution (0–350 V/m, color-coding)
and (C) a directionally encoded color map of anisotropic tissue conductivity (principal conductivity vector) of
the brain model. In panel C, the standard color convention was used, with green representing the anterior-
posterior direction, red the left-right (transverse) direction and blue the cranio-caudal direction.
https://doi.org/10.1371/journal.pone.0179214.g005
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tumor has low conductance in A/P direction (making the better conducting tumor the “pre-
ferred” current pathway). As shown in Fig 8, this assumption was confirmed, and in fact the
A/P pair induced a median field of 161 V/m, while the L/R pair induced a significantly lower
median field (75 V/m). Thus, the distribution of the field in a particular region may to some
extent be predicted by visual inspection of the directionally encoded color map of tissue diffu-
sion (and hence the conductivity in the tumor and its neighboring regions) and consideration
of the expected CSF current paths between active the electrode positions.
Solid vs. necrotic tumor core and the differences between L/R and A/P
electrode pairs
As a general observation, median field strengths induced in solid tumors were nearly identical
to those induced in necrotic tumors regardless of the direction or extent of displacement (Fig
Fig 6. Current density. (A) Sagittal and (B) axial section showing current density in a healthy brain. It can be seen that current density in the
ventricles is particularly high for the A/P electrode pair, supporting the notion that current generated by the A/P electrode pair might be partly shunted
through CSF and thus circumvent deeply seated tumors.
https://doi.org/10.1371/journal.pone.0179214.g006
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1). However, replacing the central necrosis with tumor tissue changed the field distribution to
be highly uniform throughout the tumor volume and less focal, as evident from Fig 9 and the
significantly lower interquartile range observed for solid tumors relative to necrotic tumors
(Fig 2B). Specifically, the current flow was preferentially oriented along pathways into the bet-
ter conductive necrosis causing increased field strengths in solid tumor parts along those path-
ways Thus the A/P electrode pair created strong fields in the anterior and posterior parts of the
necrotic tumor but weaker fields in the medial and lateral parts, and the opposite effect was
observed for the L/R pair (Fig 9). The two electrode array pairs thereby collectively covered
most of the tumor tissue, i.e. induced a high electrical field in most of the tissue at some point
in the activation cycle, while only one pair did not achieve this effect. As mentioned, this
Fig 7. Field- and current density distribution. Axial representation of the current density distribution (A) and field distribution (B) induced in a tumor by
the L/R pair. (C-E) Field distribution in tumors (encircled) with varying topographical relationship to the same sulcus (displacement along the y-axis). High
current densities are induced in the sulcus causing high field strengths in tissues located at the bottom boundary.
https://doi.org/10.1371/journal.pone.0179214.g007
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focality was much less pronounced for solid tumors, which may also be appreciated from Fig 9
and the low IQR of field estimates for solid tumors in general (Fig 2B).
This uniform distribution of the fields observed in solid tumors significantly reduced the
variability of differences in field distribution induced by the L/R and A/P pairs, respectively.
This observation is illustrated in Fig 2, which shows that tumors located superficially in the
brain (x = 45 to 50 mm) experienced nearly the same median field strength when exposed to
the L/R and A/P electrode fields, i.e. median Δ|E| 0 (Fig 2A). This observation was true for
both necrotic and solid tumors, although the local differences in field strength within the
tumor were significant for necrotic tumors, i.e. high IQR, but less pronounced for solid tumors
(low IQR). These findings indicate that some situations (e.g. small tumors with homogeneous
conductivity) may only require one electrode pair to obtain adequate field “coverage” in the
entire tumor. In such situations, the clinician may choose the electrode layout, which provides
the highest field strength. To support this notion, we reviewed tumors located deeper in the
Fig 8. Field strength in corpus callosum tumor. Topographical field distribution in a tumor located in the corpus callosum. Results for the L/R electrode
pair are shown to the left, and results for the A/P pair to the right. It is evident that higher field strengths were achieved with the A/P electrodes, most notably
in the anterior and posterior parts of the tumor shell.
https://doi.org/10.1371/journal.pone.0179214.g008
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brain (e.g. x = 30 to 37.5 mm). In these cases, the L/R pair was significantly more efficient than
the A/P pair (paired median Δ|E| 60 V/m). For solid tumors, this difference was even more
pronounced throughout most of the tumor volume due to the uniform field distribution (Fig
9). In fact, the L/R pair induced an equal or higher field strength compared to the A/P pair in
>99% of the tumor volume, which questions the feasibility of employing the A/P pair in these
cases. The same tendency was observed for necrotic tumors in this position, although the pre-
diction interval was much larger (high IQR), indicating that one electrode pair was unable to
induce sufficient field strength in the entire tumor volume. The higher efficacy of the L/R elec-
trode when treating deeply seated tumors may be related to the smaller head size in the L/R
direction (150 mm) relative to the A/P direction (190 mm). Alternatively it may be a result of
the tumor’s placement in white matter tracts with low anisotropic conductivity in the L/R
direction, which creates a preferred current pathway through the better conductive tumor and
thereby high field strengths within it. The high correlation between L/R and A/P induced fields
in solid homogeneous tumors was generally observed for most tumors, indicating that a single
Fig 9. Comparison of field distribution in necrotic and solid tumors. Topographical field distribution in a tumor with central necrosis (left column), and
the same tumor with no central necrosis (right column). The top row shows the results for the A/P electrode pair, and the bottom row for the L/R pair.
https://doi.org/10.1371/journal.pone.0179214.g009
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pair may suffice to cover the entire tumor. However, for superficial tumors, the absolute differ-
ence between A/P and L/R field strengths was negligible, indicating that neither pair should be
preferred over the other.
Displacement of solid tumors in the y- and z- directions showed no clear trend in median
or IQR of the field difference, and the latter estimates were generally comparable for the A/P
and L/R electrode pairs respectively (Fig 6). Again, IQR was significantly lower for solid
tumors, as observed for displacement in the x direction.
Discussion
In this study, we used a realistic head model constructed from MRI data to assess the field dis-
tribution induced by TTFields therapy. Specifically, we digitally introduced a series of both
necrotic and solid tumors at various positions in the brain to investigate the influence of tumor
location relative to surrounding tissue and electrode placement on the efficacy of TTFields.
In summary, we found that electric field strength in tumor tissue was highly dependent on
differences in conductivity between the tumor and surrounding tissues, while the absolute dis-
tance to the active electrode was less important. In particular, tumors embedded in the deep
white matter were generally exposed to significantly higher field strengths during activation of
the L/R electrode pair, compared to more superficial gyral positions. Conversely, the A/P elec-
trode pair induced the highest field strength in tumors located in the superficial gyral regions.
Tumors in close proximity to a sulcus experienced high field strengths in local regions close
to the CSF. Central necrosis caused the field strength to be unevenly distributed in the tumor
volume, so that the L/R electrode pair induced high field strengths in the medial and lateral
tumor regions and lower field strengths in the anterior and posterior regions, whereas the
opposite was observed for the A/P pair. Homogeneous tumors experienced a more uniform
field distribution throughout the entire volume and generally caused the L/R and A/P field dis-
tributions to be more similar.
In general, our observations support the notion that the local field distribution induced by
TTFields is largely determined by topographical conductivity variations in the tissue. We
observed two major effects. Firstly, the high conductivity of CSF tended to create preferred
pathways for current flow, thereby shunting significant amounts of current through the CSF
space, including the sulci and ventricles. High field intensities were observed in regions, such
as the sulcal fundi, where CSF pathways lead current into less conductive tissue. Secondly, the
relatively well conductive tumor tissue, particularly for tumors with central necrosis, also cre-
ated preferred pathways for current flow, when surrounded by tissue with a lower conductiv-
ity, such as WM. By the same mechanism as described above, high fields were observed in the
regions in which the current shunted through the tumor and met the less conductive sur-
rounding WM. This observation was particularly pronounced when the current flow was per-
pendicular to the main WM fiber orientation, so that the WM conductivity in the current
direction was minimal.
Contrary to the expected, the distance between the tumor and the scalp electrodes appears
to be less important. This observation is likely related to the large spread of current, which
takes place in the skin and CSF compartments. Current is thereby not distributed focally from
the electrode to the tumor, but follows a complex pattern determined by the head geometry
and electrical properties of the conductive media. Naturally, the conductivity distributions
observed in real patients with intracranial tumors will deviate largely from the simplistic,
spherical models investigated here and elsewhere in the literature. In particular, considerable
spatial conductivity variations and tissue anisotropy may be expected in real patients,
which highlights the need for more realistic models to account for these challenges. Since
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conductivity estimates may be determined from diffusion MRI (dMRI), such images may give
clinicians an intuitive understanding of the field distribution for individual patients, although
individual calculations are required to obtain more exact and representative estimates. How-
ever, until the dMRI-based conductivity estimation and individualized field modeling has
been further validated for pathology applications, the results presented in this study provide
new and important insight into the expected efficacy of TTFields at various tumor locations.
The study is the first to present and utilize head models in which the tumors are not entirely
embedded in single tissue volumes, such as the deep white matter [28,29], but rather cross
multiple tissue boundaries. Furthermore, our results illustrate more general principles relating
the anatomic conductivity distribution to current flow and the induced TTFields distribution,
which may help clinicians obtain a better understanding of the nature of TTFields.
In addition to the above, our results also suggest that activation of a single electrode array
pair may suffice in some cases of particularly homogeneous tumors. Specifically, we found
that the L/R and A/P field distributions were highly correlated for solid tumors regardless
of tumor location. This suggests that both pairs are equally able to distribute the effect of
TTFields throughout the entire tumor volume, and that one electrode pair may therefore suf-
fice to cover the region of pathology. For medial tumor locations, the L/R pair was even con-
siderably superior to the A/P pair and induced a much stronger field (~60 V/m difference). In
such a case, it could be argued that employment of the A/P pairs would be counterproductive,
and a more rational approach would be to maximize ’on-time’ of the more effective L/R elec-
trode pair by simply using only a single electrode pair. All together these results imply that
future generations of TTFields therapy may be tailored to the individual case to minimize
equipment size and thereby cosmetic and practical disadvantages of the treatment, reduce
costs and prolong battery life for higher availability and utility of the treatment. However, it
must also be considered that the use of multiple field directions has the advantage of being
able to target cells with different direction of mitosis. This is related to the fact that TTFields
efficacy depends largely on the direction of mitosis of the exposed cell, and the effect is higher
when the field is applied in the direction of cell division [12]. Although the presented results
do not account for this circumstance, they do suggest that single electrode devices may be suit-
able in some cases if the benefit of the average field strength is higher than the expected loss of
efficiency due to single direction treatment. Future experiments are required to investigate the
clinical feasibility of such device configurations and knowledge of local directional bias must
be included.
Limitations
The investigated model represents a variety of scenarios specific for the given individual on
which the model was based. It is important to highlight that personalized modeling experi-
ments should be performed to accurately account for individual variations in anatomy such as
the size and shape of the head and tumor, as well as the variations in electrical properties of the
intracranial tissues. Such individualized approaches may provide more accurate insight into
the expected effects for the treated individual, and also potentially assist in more accurate ther-
apy planning for better safety and efficacy. Furthermore, individualized methods may also
assist in characterizing changes which may occur throughout the course of TTFields therapy,
e.g. due to changes in tumor size or tissue composition. Such changes may occur as a result of
dynamic disease development or as a result of therapy induced tissue changes. The Authors
recently published an example of individualized TTFields modeling [30].
For the present study, it should also be considered that the choice of dielectric property esti-
mates influence the model results (see Methods). Wenger et al, 2015 [29], recently reported an
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important assessment of the level of sensitivity towards dielectric property variations, which
can be expected in a FEM head model comparable to the one presented here. As evident from
that study, the choice of conductivity estimates will influence the TTFields distribution to a
significant extent, while permittivity plays only a negligible role. In that respect, it should be
noted that the results presented were obtained using a particular set of dielectric property val-
ues derived from the literature. Although thee values are commonly accepted, this poses a limi-
tation in the generalizability of the results. However, since the field changes observed with
changing tumor location in the present study are primarily driven by the relative conductivity
differences between tumor tissue, CSF and brain white matter, we suggest that the qualitative
pattern of the reported findings will also hold for a range of varying tissue conductivities, as
long as the conductivity differences stay in the same direction (i.e. CSF has higher conductivity
than the tumor, and the tumor has higher conductivity than the white matter). While the re-
ported absolute field values will clearly change when varying conductivities, we therefore
expect our main findings and general conclusions to hold in a wide range of scenarios. How-
ever, future work aiming to increase the level of anatomical detail of the head and body models
used for TTFields estimation will no doubt help to increase model accuracy, utility and robust-
ness significantly. In addition to more accurate and individualized anatomical and dielectric
representation of the treated pathology, future model frameworks may also include structures
such as venous and arterial vasculature, which are highly difficult to reproduce accurately and
which were not included in the present model. Such details may play a significant role in the
distribution of both the electrical field and the thermal energy induced by TTFields.
Conclusion
We have presented important general principles, which may be applied to guide the prediction
and interpretation of the expected field distribution in patients treated with TTFields. Our
results are based on field simulations performed on a single head model with a range of virtu-
ally incorporated tumors and using dielectric estimates from the literature. Although, this
approach is widely adopted for many objectives, it is important to bear in mind that variations
in morphology and dielectric properties may likely affect the results and conclusions. Future
work is needed to assess the sensitivity of the suggested principles towards such variations. In
addition, accurate predictions of the field distribution should ideally be based on patient spe-
cific models with accurate anatomical representation and individual dielectric estimates.
Despite these limitations, we have extracted general principles of the field distribution,
which likely hold under common physiological conditions. We find that the relationship
between median field strength and tumor location is highly complex but largely dependent on
the local differences in conductivity between the tumor and the surrounding tissues. High
fields are observed at locations where the conductive CSF pathways funnel significant amounts
of current into the tumor tissue. Equivalently, tumors embedded in less conductive WM tend
to create preferred pathways for current flow, creating high current densities and increased
field intensities in some parts of the tumor and in the surrounding (more resistive) regions.
Contrary, the absolute distance between the tumor and the active electrodes appears to be less
important. Left/right field directions are generally more effective than anterior/posterior direc-
tions. The efficiency of L/R field directions is higher for tumors embedded in the deep white
matter tracts whereas the efficiency of A/P field directions is higher for tumors in the subcorti-
cal regions. Tumors with central necrosis will likely experience a focal enhancement of the
field strength in the part of the tumor located perpendicular to the active field direction, and
the presence of central necrosis greatly affects field topography, resulting in a non-uniform
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field distribution in the tumor tissue with focal field enhancement at tumor boundaries per-
pendicular to the current.
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S1 File. Changes in L/R field topography with tumor displacement along the x-axis. Axial
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(MP4)
S2 File. Changes in A/P field topography with tumor displacement along the x-axis. Axial
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